Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2025
0mins
Should l Buy NOTV?
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NOTV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NOTV
Wall Street analysts forecast NOTV stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.255
Low
3.00
Averages
3.00
High
3.00
Current: 0.255
Low
3.00
Averages
3.00
High
3.00
About NOTV
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Issues Draft Guidance on Alternatives to Animal Testing
- Alternative Testing Methods: The FDA has issued draft guidance to assist drug developers in validating alternative methods to replace animal studies, emphasizing core validation principles for computer simulations and chemical reactivity studies, thereby modernizing drug development.
- Policy Commitment: HHS Secretary Robert F. Kennedy Jr. noted that this guidance reflects the FDA's commitment to replace animal testing with more scientifically rigorous and human-relevant methods, aiming to enhance the safety and efficacy of drug development.
- Technological Advances: FDA Commissioner Marty Makary stated that technological advancements allow drug development to move beyond animal testing, highlighting the poor track record of animal studies in predicting human safety and efficacy, thus facilitating the adoption of modern alternatives.
- Industry Impact: This guidance affects contract research organizations like Charles River Laboratories (CRL) and Inotiv (NOTV), potentially prompting these companies to adjust their preclinical testing strategies to comply with the FDA's new requirements, which could influence their market competitiveness.
See More
Inotiv, Inc. Reports Q1 2026 Earnings with Strong DSA Growth
- DSA Revenue Growth: Inotiv's DSA revenue reached $48 million in Q1 2026, reflecting a 12% year-over-year increase, with discovery and translational sciences revenue up 26% and safety assessment revenue up 7%, showcasing strong performance despite challenges in the RMS segment.
- Significant New Awards: The company secured $53.6 million in new DSA awards during the quarter, a 27% increase from the previous year, indicating enhanced customer trust and scientific capabilities, which are expected to drive future revenue growth.
- Decline in RMS Revenue: RMS revenue fell to $72.9 million, a 5.4% decrease year-over-year, primarily due to lower NHP sales volumes; management anticipates margin improvements through site optimization and cost control measures in upcoming periods.
- Debt Restructuring Progress: Inotiv is collaborating with Perella Weinberg Partners to explore potential debt refinancing options; while no formal financial guidance is provided, management maintains a cautious outlook on future market clarity, emphasizing continued focus on DSA growth and innovation.
See More
Inotiv Reports Q1 Earnings Miss with Revenue Growth
- Earnings Performance: Inotiv's Q1 GAAP EPS of -$0.83 missed expectations by $0.19, indicating challenges in profitability, while revenue of $120.88 million grew 0.8% year-over-year, aligning with market expectations and reflecting the company's efforts to stabilize income.
- Adjusted EBITDA: The adjusted EBITDA for Q1 was $1.8 million, or 1.5% of total revenue, down from $2.6 million and 2.2% in the same quarter last year, highlighting pressures on cost control and profitability.
- Book-to-Bill Ratio: The book-to-bill ratio for DSA services in Q1 was 1.16, indicating stability in new order acquisition despite profitability challenges, suggesting potential for future revenue growth.
- Backlog Growth: As of December 31, 2025, DSA backlog reached $145.4 million, up from $138.2 million on September 30, 2025, and $130.4 million on December 31, 2024, signaling positive market demand for the company's services.
See More
Inotiv to Release Q1 2026 Financial Results on February 9
- Earnings Release Schedule: Inotiv will issue its financial results for the first quarter of fiscal 2026 on February 9, 2026, before the stock market opens, demonstrating the company's commitment to transparency and information disclosure.
- Conference Call Details: On the same day, Inotiv will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results, allowing investors to engage directly by dialing 1-800-445-7795 (Domestic) or 1-785-424-1699 (International), enhancing investor relations.
- Webcast Availability: The live conference call will be accessible via the Investors section of the company's website, ensuring that those unable to attend can access an online replay, reflecting the company's dedication to investor communication.
- Company Background Information: Inotiv is a leading contract research organization focused on nonclinical and analytical drug discovery and development services, committed to increasing efficiency, improving data quality, and reducing costs associated with bringing new drugs and medical devices to market, highlighting its significant role in the industry.
See More
Inotiv Partners with LifeNet Health to Enhance Drug Development Efficiency
- Strategic Collaboration: Inotiv announces a partnership with LifeNet Health to leverage the proprietary TruVivo® system, aiming to enhance drug development efficiency and accuracy by better aligning preclinical models with human biology.
- Technological Advantage: The TruVivo® system utilizes primary human hepatocytes, providing more physiologically relevant in vitro models, thereby addressing critical challenges in drug development and potentially accelerating the development of new therapies.
- Innovation Expansion: This collaboration extends beyond liver models to other human-relevant tissue models, fostering innovation for clients addressing a wide range of human diseases and enhancing market competitiveness.
- Shared Vision: The partnership reflects a mutual mission to accelerate scientific innovation and improve patient safety, expected to bring more human-relevant technologies to clinical research, driving the development of safer and more effective therapies.
See More
Inotiv Reports Q4 FY 2025 Revenue Growth of 5.9% to $138.1 Million
- Revenue Growth: Inotiv's Q4 FY 2025 revenue reached $138.1 million, a 5.9% increase driven primarily by a 15.7% rise in Discovery and Safety Assessment (DSA) revenue, indicating strong demand in the nonclinical drug development sector.
- Reduced Operating Loss: The operating loss for Q4 decreased by 48.5% to $6.8 million, reflecting effective cost control and revenue growth strategies, suggesting an improvement in the company's financial health.
- Annual Performance Improvement: Total revenue for FY 2025 was $513.0 million, up 4.5%, with Research Models and Services (RMS) revenue increasing by 4.7%, showcasing the company's stable growth potential in the market.
- Adjusted EBITDA Improvement: Q4 adjusted EBITDA was $11.8 million, or 8.5% of total revenue, significantly up from $5.4 million in the prior year, indicating ongoing enhancements in profitability and operational efficiency.
See More
FDA Issues Draft Guidance on Alternatives to Animal Testing
- Alternative Testing Methods: The FDA has issued draft guidance to assist drug developers in validating alternative methods to replace animal studies, emphasizing core validation principles for computer simulations and chemical reactivity studies, thereby modernizing drug development.
- Policy Commitment: HHS Secretary Robert F. Kennedy Jr. noted that this guidance reflects the FDA's commitment to replace animal testing with more scientifically rigorous and human-relevant methods, aiming to enhance the safety and efficacy of drug development.
- Technological Advances: FDA Commissioner Marty Makary stated that technological advancements allow drug development to move beyond animal testing, highlighting the poor track record of animal studies in predicting human safety and efficacy, thus facilitating the adoption of modern alternatives.
- Industry Impact: This guidance affects contract research organizations like Charles River Laboratories (CRL) and Inotiv (NOTV), potentially prompting these companies to adjust their preclinical testing strategies to comply with the FDA's new requirements, which could influence their market competitiveness.
See More
Inotiv, Inc. Reports Q1 2026 Earnings with Strong DSA Growth
- DSA Revenue Growth: Inotiv's DSA revenue reached $48 million in Q1 2026, reflecting a 12% year-over-year increase, with discovery and translational sciences revenue up 26% and safety assessment revenue up 7%, showcasing strong performance despite challenges in the RMS segment.
- Significant New Awards: The company secured $53.6 million in new DSA awards during the quarter, a 27% increase from the previous year, indicating enhanced customer trust and scientific capabilities, which are expected to drive future revenue growth.
- Decline in RMS Revenue: RMS revenue fell to $72.9 million, a 5.4% decrease year-over-year, primarily due to lower NHP sales volumes; management anticipates margin improvements through site optimization and cost control measures in upcoming periods.
- Debt Restructuring Progress: Inotiv is collaborating with Perella Weinberg Partners to explore potential debt refinancing options; while no formal financial guidance is provided, management maintains a cautious outlook on future market clarity, emphasizing continued focus on DSA growth and innovation.
See More
Inotiv Reports Q1 Earnings Miss with Revenue Growth
- Earnings Performance: Inotiv's Q1 GAAP EPS of -$0.83 missed expectations by $0.19, indicating challenges in profitability, while revenue of $120.88 million grew 0.8% year-over-year, aligning with market expectations and reflecting the company's efforts to stabilize income.
- Adjusted EBITDA: The adjusted EBITDA for Q1 was $1.8 million, or 1.5% of total revenue, down from $2.6 million and 2.2% in the same quarter last year, highlighting pressures on cost control and profitability.
- Book-to-Bill Ratio: The book-to-bill ratio for DSA services in Q1 was 1.16, indicating stability in new order acquisition despite profitability challenges, suggesting potential for future revenue growth.
- Backlog Growth: As of December 31, 2025, DSA backlog reached $145.4 million, up from $138.2 million on September 30, 2025, and $130.4 million on December 31, 2024, signaling positive market demand for the company's services.
See More
Inotiv to Release Q1 2026 Financial Results on February 9
- Earnings Release Schedule: Inotiv will issue its financial results for the first quarter of fiscal 2026 on February 9, 2026, before the stock market opens, demonstrating the company's commitment to transparency and information disclosure.
- Conference Call Details: On the same day, Inotiv will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results, allowing investors to engage directly by dialing 1-800-445-7795 (Domestic) or 1-785-424-1699 (International), enhancing investor relations.
- Webcast Availability: The live conference call will be accessible via the Investors section of the company's website, ensuring that those unable to attend can access an online replay, reflecting the company's dedication to investor communication.
- Company Background Information: Inotiv is a leading contract research organization focused on nonclinical and analytical drug discovery and development services, committed to increasing efficiency, improving data quality, and reducing costs associated with bringing new drugs and medical devices to market, highlighting its significant role in the industry.
See More
Inotiv Partners with LifeNet Health to Enhance Drug Development Efficiency
- Strategic Collaboration: Inotiv announces a partnership with LifeNet Health to leverage the proprietary TruVivo® system, aiming to enhance drug development efficiency and accuracy by better aligning preclinical models with human biology.
- Technological Advantage: The TruVivo® system utilizes primary human hepatocytes, providing more physiologically relevant in vitro models, thereby addressing critical challenges in drug development and potentially accelerating the development of new therapies.
- Innovation Expansion: This collaboration extends beyond liver models to other human-relevant tissue models, fostering innovation for clients addressing a wide range of human diseases and enhancing market competitiveness.
- Shared Vision: The partnership reflects a mutual mission to accelerate scientific innovation and improve patient safety, expected to bring more human-relevant technologies to clinical research, driving the development of safer and more effective therapies.
See More
Inotiv Reports Q4 FY 2025 Revenue Growth of 5.9% to $138.1 Million
- Revenue Growth: Inotiv's Q4 FY 2025 revenue reached $138.1 million, a 5.9% increase driven primarily by a 15.7% rise in Discovery and Safety Assessment (DSA) revenue, indicating strong demand in the nonclinical drug development sector.
- Reduced Operating Loss: The operating loss for Q4 decreased by 48.5% to $6.8 million, reflecting effective cost control and revenue growth strategies, suggesting an improvement in the company's financial health.
- Annual Performance Improvement: Total revenue for FY 2025 was $513.0 million, up 4.5%, with Research Models and Services (RMS) revenue increasing by 4.7%, showcasing the company's stable growth potential in the market.
- Adjusted EBITDA Improvement: Q4 adjusted EBITDA was $11.8 million, or 8.5% of total revenue, significantly up from $5.4 million in the prior year, indicating ongoing enhancements in profitability and operational efficiency.
See More
